PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)

The aim of this study is to evaluate the efficacy and safety of PARP Inhibition and programmed cell death protein-1 (PD-1) blockade immunotherapy with concurrent stereotactic body radiotherapy (SBRT) for metastatic or advanced bone and soft tissue sarcoma.

Trial Details

NCT ID
NCT06074692
Phase
PHASE2
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Liposarcoma Sarcoma
Interventions
  • Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Written informed consent signed before any trial-related procedures are carried out
  • Histologically confirmed high-grade sarcoma of bone or soft tissue; the lesion has distant metastasis or is locally advanced and cannot be complete…
  • Have received at least one systemic treatment regimen(s) at the time of enrollment, and have not received prior PARP inhibitor treatment.
  • With measurable lesions according to Response Evaluation Criteria in Solid Tumors (RECIST1.1);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liposarcoma Sarcoma Trials on Trialify →